December 13, 2019
December 13, 2019 – The U.S. FDA has approved an expanded indication for Tiglutik® (riluzole) oral
suspension, manufactured by ITF Pharma. Under the expansion, the product can now be administered via percutaneous endoscopic gastrostomy (PEG) tubes to treat amyotrophic lateral sclerosis (ALS).